Results 91 to 100 of about 49,244 (195)

Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis

International Journal of Infectious Diseases, 2019
Objectives: Lassa fever (LF) causes annual outbreaks in endemic regions with high mortality of symptomatic patients. Ribavirin is recommended as standard treatment for LF in national and international guidelines but the evidence base for this ...
Kirsten Alexandra Eberhardt, Johannes Mischlinger, Sabine Jordan, Mirjam Groger, Stephan Günther, Michael Ramharter   +5 more
doaj   +1 more source

Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C

, 2013
Elderly patients with chronic hepatitis C have a reduced responsiveness to antiviral therapy with Peg-interferon and ribavirin. The dose reduction or the discontinuation of ribavirin due to the occurrence of anaemia is one of the most important causes ...
P. Guerzoni, B. Omazzi, G. Borroni, R. Ceriani, F. Salerno, M. Cazzaniga, M. Andreoletti, A. Prada, G. Spinzi, N. Terreni, M. G. L. Pich   +10 more
core   +1 more source

Analysis of ribavirin mutagenicity in human hepatitis C virus infection [PDF]

, 2007
10 pages, 2 figures, 6 tables.The addition of ribavirin to alpha interferon therapy significantly increases response rates for patients with chronic hepatitis C virus (HCV) infection, but ribavirin's antiviral mechanisms are unknown.
Lázaro, Ester, Pawlotsky, Jean-Michel, Hézode, Christophe, Brillet, Rozenn, Chevaliez, Stéphane   +4 more
core   +1 more source

Error-Prone Replication of West Nile Virus Caused by Ribavirin

, 2005
Ribavirin has been reported to cause error-prone replication and viral extinction in RNA viruses. The antiviral activity of ribavirin against West Nile virus (WNV) was evaluated in various cell lines to select a model in which mutagenic effects could be ...
Yamshchikov, V. F., Julander, Justin G., Sidwell, R. W., Day, C. W., Smee, Donald F., Morrey, John D.   +5 more
core   +1 more source

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic Hepatitis C virus infection in a European cohort: A cross-sectional study [PDF]

, 2011
Background To date, drug response genes have not proved as useful in clinical practice as was anticipated at the start of the genomic era. An exception is in the treatment of chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon-
Hellard, M, Powell, Elizabeth, Ahlenstiel, G., Smedile, Antonina, Bassendine, Margaret, Hammond, E., O'Connor, Kate S, Armstrong, Nicola J, Stewart, Graeme J, Müller Tobias, Silvana Gaudieri, Mallal Simon, Armstrong Nicola J., Powell Elizabeth, Graeme J Stewart, Bassendine, M, Abate, ML, Jacob Nattermann, Irving, WL, Ahlenstiel, G, Simon Mallal, Negro, F, Stewart, Graeme J., Suppiah, Vijayaprakash, Matthews, G, Suppiah Vijayaprakash, Gaudieri Silvana, Bochud Pierre-Yves, null null, Nattermann, J, Vijayaprakash Suppiah, Hammond, Emma, Graeme J. Stewart, Hellard Margaret, Bochud, P-Y, Mallal, S., Negro, F., Ahlenstiel, Golo (R18999), O'Connor, KS, Smedile, A, Booth, DR, Powell, E, George Jacob, Gaudieri, S., Negro Francesco, Pierre-Yves Bochud, Irving, W.L., David Dunn, Abate, Maria L., Dore Gregory J., Hellard, M., International Hepatitis C Genetics Consortium (IHCGC), Spengler, U., William L Irving, Dunn David, David Sheridan, Riordan Stephen, Berg Thomas, Dunn, D.S., Stewart Graeme J., Mathews, Gail, Weltman, Martin, Ulrich Spengler, Nattermann Jacob, Mallai, Simon, Dunn, D, Francesco Negro, Berg, Thomas, for the International Hepatitis C Genetics Consortium (IHCGC), Gregory J. Dore, Sheridan, D, Abate Maria Lorena, Jacob George, Nicola J Armstrong, Matthews Gail, Mallal, S, Matthews, Gail, Booth, David R, Dore, G.J., Müller, T., Kate S O'Connor, Armstrong, Nicola J., Dore, Gregory J, Gail Matthews, Spengler Ulrich, Müller, T, Booth, David R., Berg, T., Irving, William L., Spengler, U, Booth, D.R., Spengler, Ulrich, Suppiah, V, Powell, E., Martin Weltman, Emma Hammond, Dunn, David, Thomas Berg, Suppiah, Vijay, Matthews, G., Abate, Maria Lorena, Bassendine, M., Berg, T, Riordan, Stephen, Hammond, E, Muller, Tobias, Ahlenstiel, Golo, Nattermann, J., Sheridan David, Smedile Antonina, Kate S. O'Connor, Mallal, Simon, Sheridan, D., Hammond Emma, David R. Booth, Irving William L., Stewart, GJ, Maria Lorena Abate, O'Connor, Kate S., Antonina Smedile, Golo Ahlenstiel, Armstrong, N.J., Margaret Hellard, Dore, GJ, O'Connor Kate S., Gaudieri, S, Hellard, Margaret, David R Booth, Weltman Martin, Riordan, S, Irving, William L, Margaret Bassendine, Tobias Müller, Armstrong, NJ, Weltman, M., Bassendine Margaret, Booth David R., Elizabeth Powell, Smedile, A., William L. Irving, Dore, Gregory J., Stephen Riordan, Weltman, M, Sheridan, David, Negro, Francesco, Bochud, PY, Riordan, S., Bochud, Pierre-Yves, Gregory J Dore, O'Connor, K.S., George, J, Nicola J. Armstrong, Suppiah, V., Stewart, G.J., Ahlenstiel Golo, George, J., George, Jacob, Nattermann, Jacob, Abate, M.L., Gaudieri, Silvana   +159 more
core   +1 more source

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin

Viruses, 2012
It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C.
Osamu Yokosuka, Fumio Imazeki, Makoto Arai, Keiichi Fujiwara, Xia Jiang, Shuang Wu, Shingo Nakamoto, Tatsuo Kanda, Tatsuo Miyamura   +8 more
doaj   +1 more source

Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation

, 2009
Hepatitis C virus (HCV) infection invariably recurs after liver transplantation (LT), leading to significant morbidity and mortality. Although the combination of pegylated interferon-alpha (IFN-alpha)/ribavirin is the preferred treatment for these ...
Dinges, S., Negro, F., Clavien, P.-A., Clavien, P-A, Mentha, G, Giostra, E, Dufour, J.-F., Clavien, P A, Müllhaupt, B, Giostra, E., Heim, M., Morard, Isabelle, Mentha, Gilles, Negro, F, Negro, Francesco, Morard, I, Heim, M, Dufour, Jean-François, Dufour, J-F, Dinges, S, Dufour, J F, Giostra, Emiliano, Mentha, G., Müllhaupt, B., Morard, I., Dufour JF, Mentha G, Clavien PA, Giostra E, Morard I, Dinges S, Heim M, Negro F, Müllhaupt B   +33 more
core   +1 more source

Ribavirin induces the p53 protein expression and phosphorylation.

, 2012
(A) Dose-dependent expression and phosphorylation of p53 induced by ribavirin. HepG2 cells were treated with the indicated doses of ribavirin (0, 5, 10, 30, 100 µg/ml) for 24 h. (B) The time-course p53 expression during ribavirin treatment.
Wei-Liang Liu (138279), Hurng-Yi Wang (130558), Ming-Yang Lai (138312), Chih-Chiang Wang (138296), Hui-Ling Chen (138302), Ding-Shinn Chen (53409), Wen-Cheng Su (138291), Hung-Chih Yang (138284), Wen-Hung Huang (138307)   +8 more
core   +1 more source

Modeling Ribavirin‐Induced Anemia in Patients with Chronic Hepatitis C Virus

CPT: Pharmacometrics & Systems Pharmacology, 2016
Ribavirin remains an important component of hepatitis C treatment in certain clinical scenarios, but it causes hemolytic anemia. A quantitative understanding of the ribavirin exposure‐anemia relationship is important in dose individualization ...
LS Wu, LC Jimmerson, CE MacBrayne, JJ Kiser, DZ D'Argenio   +4 more
doaj   +1 more source

Mouse survival following ribavirin treatment.

, 2013
Percent survival of mice treated with PBS or ribavirin and infected SC or by aerosol with RVFV (n = 10/group).
Joshua Shamblin (399489), Lisa E. Hensley (202167), Darci R. Smith (399491), Gene Olinger (399490), Ginger Donnelly (399488), Catherine Wilhelmsen (399485), Kenny Lin (399484), Brian Friedrich (399486), Ashley Keeney (399487), Christopher Reed (399483), Aysegul Nalca (233873)   +10 more
core   +1 more source